Minimizing the severity of rhBMP-2-induced inflammation and heterotopic ossification with a polyelectrolyte carrier incorporating heparin on microbead templates

Spine

Volumn 38, Issue 17, 2013, Pages 1452-1458

  Wang, Ming ^a,b   Abbah, Sunny Akogwu ^a   Hu, Tao ^a   Toh, Soo Yein ^a   Lam, Raymond Wing Moon ^a   Goh, James Choh Hong ^a,c   Wong, Hee Kit ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

alginate microbeads; BMP 2 complications; control release; heparin; heterotopic ossifi cation; localization of bone formation; polyelectrolyte complexes; posterior spinal fusion; rat model; seroma

Indexed keywords

COLLAGEN SPONGE; HEPARIN; POLYELECTROLYTE; POLYLYSINE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE GROWTH; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; HETEROTOPIC OSSIFICATION; LOW DRUG DOSE; MICRO-COMPUTED TOMOGRAPHY; MICROTECHNOLOGY; NONHUMAN; POSTERIOR SPINE FUSION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SEROMA;

EID: 84882456481     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e31828a3504     Document Type: Article

References (36)

1. Anderson CL, Whitaker MC. Heterotopic ossifi cation associated with recombinant human bone morphogenetic protein-2 (infuse) in posterolateral lumbar spine fusion: a case report. Spine (Phila Pa 1976) 2012;37:E502-6.
2. Kim DH, Rhim R, Li L, et al. Prospective study of iliac crest bone graft harvest site pain and morbidity. Spine J 2009;9:886-92.
3. Hsu WK, Wang JC. The use of bone morphogenetic protein in spine fusion. Spine J 2008;8:419-25.
4. Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009;302:58-66.
5. Ong KL, Villarraga ML, Lau E, et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) 2010;35:1794-800.
6. Lad SP, Nathan JK, Boakye M. Trends in the use of bone morphogenetic protein as a substitute to autologous iliac crest bone grafting for spinal fusion procedures in the United States. Spine (Phila Pa 1976) 2011;36:E274-81.
7. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profi le of bone morphogenetic protein in spine surgery. Neurosurgery 2008;62:423-31.
8. Haid RW, Jr, Branch CL, Jr, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 2004;4:527-38;discussion 38-9.
9. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976) 2007;32:2885-90.
10. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011;11:471-91.
11. Mroz TE, Wang JC, Hashimoto R, et al. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 2010;35:S86-104.
12. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 2006;31:2813-9.
13. Boakye M, Mummaneni PV, Garrett M, et al. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine 2005;2:521-5.
14. Perri B, Cooper M, Lauryssen C, et al. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. Spine J 2007;7:235-9.
15. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006;31:542-7.
16. Center for Devices and Radiological Health. Public Health Notifi cations (Medical devices)-FDA Public Health Notifi cation: life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. Available at: http://www.fda.gov/MedicalDevices/Safety/ AlertsandNotices/Public HealthNotifi cations/ucm062000.htm. Accessed September 1, 2012.
17. Luginbuehl V, Meinel L, Merkle HP, et al. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm 2004;58:197-208.
18. Friess W, Uludag H, Foskett S, et al. Characterization of absorbable collagen sponges as rhBMP-2 carriers. Int J Pharm 1999;187:91-9.
19. Abbah SA, Liu J, Goh JC, et al. Enhanced control of in vivo bone formation with surface functionalized alginate microbeads incorporating heparin and rhBMP-2. [published ahead of print November 7, 2012] Tissue Eng Part A 2013;19:350-9. doi: 10.1089/ten.TEA.2012.0274.
20. Matsumoto T, Toyoda H, Dohzono S, et al. Effi cacy of interspinous process lumbar fusion with recombinant human bone morphogenetic protein-2 delivered with a synthetic polymer and betatricalcium phosphate in a rabbit model. [published ahead of print December 28, 2011] Eur Spine J 2012;21:1338-45. doi: 10.1007/s00586-011-2130-x.
21. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-5.
22. Egan KP, Brennan TA, Pignolo RJ. Bone histomorphometry using free and commonly available software. [published ahead of print August 8, 2012] Histopathology 2012;61:1168-73. doi: 10.1111/j.1365-2559.2012.04333.x.
23. Parfi tt AM. Bone histomorphometry: proposed system for standardization of nomenclature, symbols, and units. Calcif Tissue Int 1988;42:284-6.
24. Parfi tt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
25. Vaidya R, Carp J, Sethi A, et al. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur Spine J 2007;16:1257-65.
26. Danino T, Volfson D, Bhatia SN, et al. In-silico patterning of vascular mesenchymal cells in three dimensions. PLoS One 2011;6:e20182.
27. Zara JN, Siu RK, Zhang X, et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and infl ammation in vivo. Tissue Eng Part A 2011;17:1389-99.
28. Patel VV, Zhao L, Wong P, et al. Controlling bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth using fi brin glue. Spine (Phila Pa 1976) 2006;31:1201-6.
29. Bridges AW, Garcia AJ. Anti-infl ammatory polymeric coatings for implantable biomaterials and devices. J Diabetes Sci Technol 2008;2:984-94.
30. Lee KB, Taghavi CE, Song KJ, et al. Infl ammatory characteristics of rhBMP-2 in vitro and in an in vivo rodent model. Spine 2011;36:E149-54.
31. Miyazaki M, Morishita Y, He W, et al. A porcine collagen-derived matrix as a carrier for recombinant human bone morphogenetic protein-2 enhances spinal fusion in rats. Spine J 2009;9:22-30.
32. Kolambkar YM, Boerckel JD, Dupont KM, et al. Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of segmental bone defects. Bone 2011;49:485-92.
33. Jiao X, Billings PC, O'Connell MP, et al. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 2007;282:1080-6.
34. Flaumenhaft R, Rifkin DB. Extracellular matrix regulation of growth factor and protease activity. Curr Opin Cell Biol 1991;3:817-23.
35. Hudalla GA, Murphy WL. Biomaterials that regulate growth factor activity via bioinspired interactions. Adv Funct Mater 2011;21:1754-68.
36. Benoit DS, Durney AR, Anseth KS. The effect of heparinfunctionalized PEG hydrogels on three-dimensional human mesenchymal stem cell osteogenic differentiation. Biomaterials 2007;28:66-77.